Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPP1CA | P62136 | 2/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.48 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9880156 | 1.00 | PPP1CA (0.49) | PPP1CASIGMAR1LMNAKDM4EOPRM1 | |
| SCHEMBL14135618 | 1.00 | PPP1CA (0.49) | PPP1CASIGMAR1LMNAKDM4EOPRM1 | |
| SCHEMBL13002108 | 0.88 | SIGMAR1 (0.45) | SIGMAR1OPRM1ALDH1A1GAAHSD17B10 | |
| SCHEMBL9880155 | 0.88 | MEN1 (0.54) | SIGMAR1OPRM1ALDH1A1GAAHSD17B10 | |
| SCHEMBL18857096 | 0.84 | PPP1CA (0.51) | PPP1CALMNAKDM4ETFPI2GAA | |
| SCHEMBL9871216 | 0.79 | LTA4H (0.60) | SIGMAR1OPRM1ALDH1A1GAAHSD17B10 | |
| SCHEMBL14878065 | 0.78 | DRD3 (0.46) | SIGMAR1ALDH1A1 | |
| SCHEMBL9872534 | 0.77 | DRD4 (0.64) | SIGMAR1OPRM1ALDH1A1 | |
| SCHEMBL3495133 | 0.76 | SMN1; SMN2 (0.68) | PPP1CASIGMAR1LMNATFPI2 | |
| SCHEMBL13311736 | 0.76 | SMN1; SMN2 (0.68) | PPP1CASIGMAR1LMNATFPI2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10399993-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180370983-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | LIXTE BIOTECHNOLOGY, INC. (US) | 2018-12-27 | — | — | US | disclosed |
| US-10023587-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170369503-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | LIXTE BIOTECHNOLOGY, INC. (US) | 2017-12-28 | — | — | US | disclosed |
| EP-2124550-B1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | LIXTE BIOTECHNOLOGY INC (US) | 2017-04-19 | — | — | EP | disclosed |
| US-20160264593-A1 | PROTEIN PHOSPHATASE INHIBITORS THAT CROSS THE BLOOD BRAIN BARRIER | LIXTE BIOTECHNOLOGY, INC. | 2016-09-15 | — | — | US | disclosed |
| US-9079917-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-9079917-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20150045373-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | LIXTE BIOTECHNOLOGY, INC. | 2015-02-12 | — | — | US | disclosed |
| US-20150045373-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | LIXTE BIOTECHNOLOGY, INC. | 2015-02-12 | — | — | US | disclosed |
| US-8426444-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426444-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-20120270736-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | LIXTE BIOTECHNOLOGY, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120270736-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | LIXTE BIOTECHNOLOGY, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-7998957-B2 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998957-B2 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998957-B2 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20090036309-A1 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. | 2009-02-05 | — | — | US | disclosed |
| US-20090036309-A1 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. | 2009-02-05 | — | — | US | disclosed |
| US-20090036309-A1 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270736-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | HCCS, OXA1L, OTC | PPP1CA 3251/4885SIGMAR1 1219/4885LMNA 2628/4885 |
| US-20150045373-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | HCCS, OXA1L, OTC | PPP1CA 3251/4885SIGMAR1 1219/4885LMNA 2628/4885 |
| US-20160264593-A1 | PROTEIN PHOSPHATASE INHIBITORS THAT CROSS THE BLOOD BRAIN BARRIER | DUSP1, PPP5C, DUSP15 | PPP1CA 36/4885SIGMAR1 4401/4885LMNA 4393/4885 |
| US-20090036309-A1 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | HCCS, VHL, OXA1L | PPP1CA 3354/4885SIGMAR1 1727/4885LMNA 2379/4885 |
| US-10399993-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | HCCS, OXA1L, OTC | PPP1CA 3251/4885SIGMAR1 1219/4885LMNA 2628/4885 |
| US-20180370983-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | HCCS, OXA1L, OTC | PPP1CA 3251/4885SIGMAR1 1219/4885LMNA 2628/4885 |
| US-20170369503-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | HCCS, OXA1L, OTC | PPP1CA 3251/4885SIGMAR1 1219/4885LMNA 2628/4885 |
| US-10023587-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | HCCS, OXA1L, OTC | PPP1CA 3251/4885SIGMAR1 1219/4885LMNA 2628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.